Arginine inhibits hemostasis activation
Arginine inhibits hemostasis activation
复制标题
DOI：
10.1016/s0049-3848(01)00368-1
复制
发表时间：
2001-11-15
影响因子：
7.5
通讯作者：
Renz, H
中科院分区：
文献类型：
--
作者：
Stief, TW;Weippert, M;Renz, H
背景：活体止血激活的诊断和治疗具有重要的临床意义。必须防止体外止血的人工改变(即凝血或纤溶)。通常情况下，柠檬酸钠的体外抗凝并不能完全抑制凝血或纤溶活性。因此，在止血激活的诊断和治疗中，都需要一种简单的止血激活生理学抑制剂。方法：测定正常人全血或血浆中全血凝血时间、凝血酶原时间、活化部分凝血活酶时间、体外出血试验关闭时间和全血聚集率。结果：5-100 mM的精氨酸对WBCT、PT、APTT、IVBT-CT和WBA均有抑制作用。精氨酸(50 MM)使WBCT、PT或IVBT-CT延长2倍(抗肾上腺素作用优于抗ADP作用)，APTT延长4倍或WBA抑制60%。结论：L-精氨酸(或胍)可抑制止血活性。精氨酸可作为止血稳定剂用于活动性止血的诊断和治疗。精氨酸作为一种体外止血抑制剂可用于药物溶栓或弥散性血管内凝血(DIC)中止血活性的诊断。精氨酸稳定可改善血液或血液制品的储存。氨基酸(和一氧化氮前体)L精氨酸可能是一种有趣的新药物，可以抑制病理性止血激活。(C)2001爱思唯尔科学有限公司。保留所有权利。
Background: The diagnosis and the therapy of in vivo hemostasis activation is of great clinical importance. Artefactual changes of the hemostasis (i.e., coagulation or fibrinolysis) in vitro have to be prevented. Usual in vitro anticoagulation by sodium citrate does not fully inhibit coagulation - or fibrinolysis - activation. Therefore, there is need for a simple physiologic inhibitor of hemostasis activation both in diagnosis and therapy of hemostasis activation. Methods: Whole blood clotting time (WBCT), prothrombin time (PT), activated partial thromboplastin time (APTT), in vitro bleeding test closure time (IVBT-CT), and whole blood aggregometry (WBA) were determined in normal human blood or plasma, supplemented with increasing concentrations Of L-arginine or guanidine. Results: Arginine in concentrations of 5-100 mM inhibited the WBCT, PT, APTT, IVBT-CT, and WBA. Arginine (50 mM) resulted in a two-fold prolongation of WBCT, PT, or IVBT-CT (the anti-epinephrine action is superior to the anti-ADP action), a four-fold prolongation of APTT or a 60% inhibition of WBA. Conclusion: L-Arginine (or guanidine) inhibited the activation of hemostasis. Arginine might be used as hemostasis stabilizer both in the diagnosis and therapy of hemostasis activation. The usage of arginine as an in vitro hemostasis inhibitor might be indicated in the diagnosis of hemostasis activation, as occuring in pharmacological thrombolysis or disseminated intravascular coagulation (DIC). The storage of blood or blood products might be improved by arginine stabilization. The amino acid (and nitric oxide precursor) L-arginine could be an interesting new pharmacologic agent to inhibit a pathologic hemostasis activation. (C) 2001 Elsevier Science Ltd. All rights reserved.